51
|
Papp Z, Babiuk LA, Baca-Estrada ME. The effect of pre-existing adenovirus-specific immunity on immune responses induced by recombinant adenovirus expressing glycoprotein D of bovine herpesvirus type 1. Vaccine 1999; 17:933-43. [PMID: 10067700 DOI: 10.1016/s0264-410x(98)00279-5] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
We investigated whether pre-existing adenovirus-specific immunity influenced the development of immunity to a foreign antigen expressed by recombinant adenovirus. Active adenovirus-specific immunity was induced in cotton rats by i.n. administration of wild type human adenovirus type 5 (HAd5) two weeks before immunisation with a HAd5 vector expressing the glycoprotein D (gD) of bovine herpesvirus type 1 (gD-dE3 recombinant adenovirus). Active adenovirus-specific immunity inhibited gD-specific immune responses, following either i.n. or gastrointestinal immunisation with gD-dE3. An inhibitory effect was present even if infection with HAd5 and immunisation with gD-dE3 were 13 weeks apart. Passive transfer of adenovirus specific antibodies to cotton rats one day before immunisation, however, did not significantly inhibit gD-specific immune responses induced by i.n. immunisation with gD-dE3. Repeated administration of an adenovirus vector, therefore, may have a limited ability to deliver antigen, while passive immunity to adenovirus may not interfere with the success of immunisation.
Collapse
Affiliation(s)
- Z Papp
- Veterinary Infectious Disease Organization, University of Saskatchewan, Saskatoon, Canada
| | | | | |
Collapse
|
52
|
Kalus RM, Kantor JA, Gritz L, Gómez Yafal A, Mazzara GP, Schlom J, Hodge JW. The use of combination vaccinia vaccines and dual-gene vaccinia vaccines to enhance antigen-specific T-cell immunity via T-cell costimulation. Vaccine 1999; 17:893-903. [PMID: 10067696 DOI: 10.1016/s0264-410x(98)00275-8] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Several recombinant vaccinia viruses are currently being evaluated to induce antigen-specific immunity to a variety of infectious disease agents and tumor associated antigens. T-cell costimulation is extremely important in enhancing T-cell responses, and recombinant vaccines have now been shown to be effective vectors to express a range of these molecules. Both combination vaccines (an admixture of a recombinant vaccinia virus expressing a specific target antigen and a recombinant vaccinia virus expressing a costimulatory molecule) and dual-gene vaccines expressing both transgenes on the same vector have been shown capable of effectively enhancing antigen-specific responses via T-cell costimulation. In this report, we compare for the first time the use of both types of approaches to enhance antigen-specific T-cell responses, and we demonstrate the importance of route of vaccine administration and vaccine dose in attaining optimal T-cell responses. These studies should have direct bearing on the design of vaccine clinical trials for infectious agents and/or tumor associated antigens, in which T-cell costimulatory molecules will be employed to enhance antigen-specific T-cell responses via the use of either combination or dual-gene vaccinia vaccines.
Collapse
MESH Headings
- Adjuvants, Immunologic/genetics
- Adjuvants, Immunologic/pharmacology
- Animals
- B7-1 Antigen/genetics
- B7-1 Antigen/immunology
- Carcinoembryonic Antigen/genetics
- Carcinoembryonic Antigen/immunology
- Epitopes, T-Lymphocyte/immunology
- Female
- Immunity, Cellular/immunology
- Mice
- Mice, Inbred C57BL
- T-Lymphocytes/immunology
- Transgenes/immunology
- Vaccines, Combined/genetics
- Vaccines, Combined/immunology
- Vaccines, DNA/genetics
- Vaccines, DNA/immunology
- Vaccines, Synthetic/immunology
- Vaccinia virus/genetics
- Vaccinia virus/immunology
- Viral Vaccines/genetics
- Viral Vaccines/immunology
- Viral Vaccines/pharmacology
Collapse
Affiliation(s)
- R M Kalus
- Howard Hughes Medical Institute, Research Scholar's Program at the NIH, Bethesda, MD 20892, USA
| | | | | | | | | | | | | |
Collapse
|
53
|
Berglund P, Fleeton MN, Smerdou C, Liljeström P. Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice. Vaccine 1999; 17:497-507. [PMID: 10073729 DOI: 10.1016/s0264-410x(98)00224-2] [Citation(s) in RCA: 92] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
The replicon of Semliki Forest virus (SFV) offers the possibility to direct high-level, transient expression of heterologous proteins in vivo. We initiated studies to determine the possibility of employing the SFV expression system for recombinant vaccine purposes. Mice immunized with recombinant SFV encoding Influenza A nucleoprotein (NP) or E. coli LacZ developed long-lasting antigen-specific IgG levels and induction of cytotoxic T-cell (CTL) memory that persisted for over one year. Predominantly type 1 T-helper cells were induced as shown by IgG subclass ELISA. Humoral and cell-mediated immune responses could be induced upon delivery by several administration routes and mucosal immunizations induced secretory IgA in the respiratory tract. Development of immune responses against the vector itself did not inhibit boost responses by subsequent immunizations with recombinant SFV. Immunization of mice with vectors encoding the Influenza A virus antigens nucleoprotein (NP) and hemagglutinin (HA) resulted in immune responses that were protective against challenge infection with Influenza virus.
Collapse
Affiliation(s)
- P Berglund
- Microbiology and Tumorbiology Center, Karolinska Institute, Stockholm, Sweden
| | | | | | | |
Collapse
|
54
|
Bouwer HG, Shen H, Fan X, Miller JF, Barry RA, Hinrichs DJ. Existing antilisterial immunity does not inhibit the development of a Listeria monocytogenes-specific primary cytotoxic T-lymphocyte response. Infect Immun 1999; 67:253-8. [PMID: 9864223 PMCID: PMC96304 DOI: 10.1128/iai.67.1.253-258.1999] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/1998] [Accepted: 10/28/1998] [Indexed: 11/20/2022] Open
Abstract
Infection of BALB/c mice with Listeria monocytogenes stimulates an antilisterial immune response evident by the appearance of H2-Kd-restricted CD8(+) cytotoxic T lymphocytes (CTLs) specific for the nanomer peptides amino acids (aa) 91 to 99 of listeriolysin O (LLO 91-99) and aa 217 to 225 of the p60 molecule (p60 217-225). We have introduced point mutations at anchor residues within LLO 91-99 (92F) or p60 217-225 (218F), and BALB/c mice infected with L. monocytogenes strains containing these point mutations do not develop CTLs specific for LLO 91-99 or p60 217-225, respectively. We have used these strains to test whether primary CTL responses against L. monocytogenes-derived determinants can be stimulated within an environment of existing antilisterial immunity. We found that the development of a primary L. monocytogenes-specific CTL response is not altered by existing immunity to L. monocytogenes. For example, primary immunization with the p60 218F strain of L. monocytogenes followed by a secondary immunization with wild-type L. monocytogenes results in stimulation of p60 217-225-specific CTLs at primary response levels and LLO 91-99-specific effectors at levels consistent with a memory CTL response. Similarly, primary immunization with the 92F strain of L. monocytogenes followed by a secondary immunization with wild-type L. monocytogenes results in stimulation of LLO 91-99-specific CTLs at primary response levels and p60 217-225-specific effectors at levels consistent with a memory CTL response. These results provide additional support for the use of L. monocytogenes as a recombinant vaccine vector and show that antivector immunity does not inhibit the development of a primary CTL response when the epitope is delivered by L. monocytogenes as the vaccine strain.
Collapse
Affiliation(s)
- H G Bouwer
- Immunology Research, Veterans Affairs Medical Center, Earle A. Chiles Research Institute, Portland, Oregon, USA.
| | | | | | | | | | | |
Collapse
|
55
|
MESH Headings
- AIDS Vaccines
- Adjuvants, Immunologic
- Administration, Intranasal
- Administration, Oral
- Animals
- Bacterial Vaccines
- China
- Europe
- Genome
- Glycoconjugates/immunology
- Haplorhini
- History, 18th Century
- History, 19th Century
- History, 20th Century
- History, Ancient
- Immunologic Memory
- Immunotherapy, Active
- Peptides/immunology
- Plants, Genetically Modified
- Replicon
- SAIDS Vaccines
- Species Specificity
- Vaccination/history
- Vaccination/methods
- Vaccines/history
- Vaccines, Attenuated
- Vaccines, Combined
- Vaccines, DNA
- Vaccines, Synthetic
- Viral Vaccines
Collapse
Affiliation(s)
- M A Liu
- Chiron Vaccines Research, Meryville, California 94608, USA
| |
Collapse
|
56
|
Hodge JW, McLaughlin JP, Kantor JA, Schlom J. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses. Vaccine 1997; 15:759-68. [PMID: 9178479 DOI: 10.1016/s0264-410x(96)00238-1] [Citation(s) in RCA: 126] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Recombinant vaccinia viruses containing tumor associated genes represent an attractive vector to induce immune responses to weak immunogens in cancer immunotherapy protocols. The property of intense immunogenicity of vaccinia proteins, however, also serves to limit the number of inoculations of recombinant vaccinia viruses. Host immune responses to the first immunization have been shown to limit the replication of subsequent vaccinations and thus reduce effectiveness of boost inoculations. The use of recombinant avian pox viruses (avipox) such as the canarypox (ALVAC) or fowlpox are potential candidates for immunization protocols in that they can infect mammalian cells and express the inserted transgene, but do not replicate in mammalian cells. We report here the construction and characterization of a canarypox (ALVAC) recombinant expressing the human carcinoembryonic antigen (CEA) gene (designated ALVAC-CEA). Antibody, lymphoproliferative and cytolytic T-cell responses as well as tumor inhibition were shown to be elicited by the ALVAC-CEA recombinant in a murine model. The utilization of a diversified immunization scheme using a recombinant vaccinia virus followed by recombinant avian pox virus was shown to be far superior than the use of either one alone in eliciting CEA-specific T-cell responses. Experiments were conducted to determine if the use of a diversified immunization scheme using a recombinant vaccinia virus (rV-CEA) and ALVAC-CEA would be superior to the use of either one alone in eliciting CEA-specific T-cell responses. When mice were immunized with rV-CEA and then ALVAC-CEA. CEA-specific T-cell responses were at least four times greater, and for superior to those achieved with three immunizations of ALVAC-CEA. Multiple boosts of ALVAC-CEA following rV-CEA immunization further potentiated anti-tumor effects and CEA specific T-cell responses. These studies demonstrate the proof of concept of the advantage of diversified immunization protocols employing both recombinant vaccinia and recombinant avipox vectors.
Collapse
Affiliation(s)
- J W Hodge
- Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
| | | | | | | |
Collapse
|
57
|
Carroll MW, Overwijk WW, Chamberlain RS, Rosenberg SA, Moss B, Restifo NP. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine 1997; 15:387-94. [PMID: 9141209 PMCID: PMC1950787 DOI: 10.1016/s0264-410x(96)00195-8] [Citation(s) in RCA: 76] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Modified vaccinia virus Ankara (MVA), a highly attenuated strain of vaccinia virus (VV) that is unable to replicate in most mammalian cells, was evaluated as an expression vector for a model tumor associated antigen (TAA) and as a potential anti-cancer vaccine. We employed an experimental murine model in which an adenocarcinoma tumor line, CT26.CL25, was stably transfected with a model TAA, beta-galactosidase (beta-gal). Mice injected intramuscularly with a recombinant MVA (rMVA) expressing beta-gal (MVA-LZ), were protected from a lethal intravenous (i.v.) challenge with CT26.CL25. In addition, splenocytes from mice primed with MVA-LZ were therapeutically effective upon adoptive transfer to mice bearing pulmonary metastases of the CT26.CL25 tumor established 3 days earlier. Most importantly, i.v. inoculation with MVA-LZ resulted in significantly prolonged survival of mice bearing three day old pulmonary metastases. This prolonged survival compared favorably to mice treated with a replication competent recombinant VV expressing beta-gal. These findings indicate that rMVA is an efficacious alternative to the more commonly used replication competent VV for the development of new recombinant anti-cancer vaccines.
Collapse
MESH Headings
- Adenocarcinoma/mortality
- Adenocarcinoma/prevention & control
- Adenocarcinoma/secondary
- Animals
- Antigens, Neoplasm/immunology
- Antigens, Tumor-Associated, Carbohydrate/biosynthesis
- Antigens, Tumor-Associated, Carbohydrate/immunology
- Cancer Vaccines/immunology
- Colonic Neoplasms/immunology
- Cytokines/biosynthesis
- Disease Models, Animal
- Female
- Genetic Vectors/immunology
- Immunization, Secondary
- Immunotherapy, Adoptive/methods
- Lung Neoplasms/mortality
- Lung Neoplasms/prevention & control
- Lung Neoplasms/secondary
- Mice
- Mice, Inbred BALB C
- Spleen/immunology
- Spleen/metabolism
- Spleen/transplantation
- Tumor Cells, Cultured
- Vaccines, Attenuated/immunology
- Vaccines, Synthetic/immunology
- Vaccinia virus/immunology
- Vaccinia virus/physiology
- Virus Replication
- beta-Galactosidase/biosynthesis
Collapse
Affiliation(s)
- M W Carroll
- Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
| | | | | | | | | | | |
Collapse
|
58
|
Abstract
The construction of vaccinia-based vaccines has been hampered by a lack of information on both the mechanisms of vaccinia-induced immunity in humans and the effect of prior exposure to vaccinia on the course of an immune response to a non-vaccinia antigen. Recent studies have investigated the immune responses induced by this virus in humans and the ability of recombinant viruses to successfully induce immunity to diverse pathogens with diverse routes of infection. In addition to the previously described ability of vaccinia to induce immune responses in experimental animals, the virus has been shown to encode modulators of immune function that may, in the future, permit the use of virus to induce qualitatively different immune responses to particular heterologous antigens.
Collapse
Affiliation(s)
- D Ulaeto
- Department of Microbiology, Oregon State University, Corvallis 97331-3804
| | | |
Collapse
|
59
|
Abstract
In addition to the introductory demonstrations of genetic immunization, the past year has brought significant advances in vaccine development. Particularly encouraging are live recombinant vaccines, studies demonstrating the potential to elicit both systemic and mucosal immune responses, more studies demonstrating immune protection in animal disease models, and experimental vaccines eliciting immune responses in primates.
Collapse
Affiliation(s)
- C K Stover
- PathoGenesis Corporation, Seattle, Washington 98119
| |
Collapse
|
60
|
Bachmann MF, Kündig TM. In vivo versus in vitro assays for assessment of T- and B- cell function. Curr Opin Immunol 1994; 6:320-6. [PMID: 8011216 DOI: 10.1016/0952-7915(94)90108-2] [Citation(s) in RCA: 26] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
As mice deficient in a particular gene provide an increasing number of novel in vivo models, in vivo assays that examine immune function are becoming a central issue. We found that the sensitivities of in vivo and in vitro assays are strikingly different. These differences have important implications for the interpretation and biological relevance of results.
Collapse
Affiliation(s)
- M F Bachmann
- Institute for Experimental Immunology, University of Zurich, Switzerland
| | | |
Collapse
|